These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 35127700)

  • 1. Inflammation and Myeloid Cells in Cancer Progression and Metastasis.
    Deng J; Fleming JB
    Front Cell Dev Biol; 2021; 9():759691. PubMed ID: 35127700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
    Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
    Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.
    Qu X; Tang Y; Hua S
    Front Immunol; 2018; 9():563. PubMed ID: 29662489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Anti-Inflammatory Agents in Prostate Cancer.
    Hatano K; Fujita K; Nonomura N
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32824865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.
    Wang J; Yu F; Jia X; Iwanowycz S; Wang Y; Huang S; Ai W; Fan D
    Int J Cancer; 2015 Mar; 136(6):E602-13. PubMed ID: 25143000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
    Sanders KL; Fox BA; Bzik DJ
    Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy.
    Lebegge E; Arnouk SM; Bardet PMR; Kiss M; Raes G; Van Ginderachter JA
    Front Immunol; 2020; 11():1395. PubMed ID: 32733461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?
    Cetintas VB; Batada NN
    J Transl Med; 2020 Jan; 18(1):45. PubMed ID: 32000794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation.
    Schmid MC; Varner JA
    J Oncol; 2010; 2010():201026. PubMed ID: 20490273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.
    Won WJ; Deshane JS; Leavenworth JW; Oliva CR; Griguer CE
    Cell Stress; 2019 Jan; 3(2):47-65. PubMed ID: 31225500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.